These side effects are derived from the residual low‐level expression of CD147 in some normal tissues,3, 13, 14 standing out CD147‐targeting therapies are not spatially restricted to cancer tissue, and peripheral toxicity may reduce the therapeutic efficacy. Here, BSG is linked to cancer.